Sandoz starts late-stage trial with copy of AbbVie’s Humira drug

LONDON (Reuters) – Sandoz, the generics division of Novartis, said on Wednesday it had initiated a late-stage clinical trial with its so-called biosimilar version of AbbVie’s best-selling drug Humira. It is Sandoz’s sixth copy of a biotech medicine to enter Phase III trials and could represent a major prize, since the Humira drug for rheumatoid arthritis, psoriasis, and Crohn’s disease is the world’s top-selling prescription product with sales of around $10 billion a year. …